Aclaris Therapeutics, Inc.
General ticker "ACRS" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $195.7M (TTM average)
Aclaris Therapeutics, Inc. follows the US Stock Market performance with the rate: 30.6%.
Estimated limits based on current volatility of 4.6%: low 2.69$, high 2.95$
Factors to consider:
- Total employees count: 91 (-13.3%) as of 2023
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Substantial additional funding needed, Economic downturns and volatility, Market volatility, Regulatory and compliance, Hybrid work model impact
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.68$, 4.75$]
- 2025-12-31 to 2026-12-31 estimated range: [1.17$, 3.39$]
Financial Metrics affecting the ACRS estimates:
- Positive: with PPE of -4.6 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -9.36 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Inventory ratio change, % of -17.20 <= -0.75
Short-term ACRS quotes
Long-term ACRS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $29.75MM | $31.25MM | $18.72MM |
| Operating Expenses | $119.61MM | $128.61MM | $160.65MM |
| Operating Income | $-89.85MM | $-97.36MM | $-141.93MM |
| Non-Operating Income | $2.95MM | $8.51MM | $9.87MM |
| R&D Expense | $77.81MM | $105.01MM | $120.49MM |
| Income(Loss) | $-86.91MM | $-88.85MM | $-132.06MM |
| Taxes | $0.00MM | $-0.37MM | $0.00MM |
| Profit(Loss)* | $-86.91MM | $-88.48MM | $-132.06MM |
| Stockholders Equity | $197.62MM | $157.18MM | $155.55MM |
| Assets | $254.60MM | $197.41MM | $220.33MM |
| Operating Cash Flow | $-67.57MM | $-78.33MM | $-20.07MM |
| Capital expenditure | $0.60MM | $1.31MM | $0.12MM |
| Investing Cash Flow | $12.63MM | $46.22MM | $-69.77MM |
| Financing Cash Flow | $72.87MM | $26.71MM | $74.54MM |
| Earnings Per Share** | $-1.33 | $-1.27 | $-1.71 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.